Samsung's new Hearapy mobile app claims to reduce motion sickness symptoms using targeted sound frequencies, specifically a 100Hz sine wave tone played for just 60 seconds. The Korean tech giant says the audio treatment can provide relief for up to two hours, marking its latest foray into health-focused consumer technology.
Key Takeaways
- Samsung's Hearapy app uses 100Hz sound frequencies to treat motion sickness in 60-second sessions
- The company claims relief can last up to two hours after a single treatment
- The app is designed to work with Galaxy Buds and represents Samsung's push into digital health solutions
The Science Behind Sound Therapy
Motion sickness affects approximately 25% to 40% of the population, according to medical research, making it a significant health concern for travelers and those sensitive to movement. Samsung's Hearapy app builds on emerging research suggesting that specific sound frequencies can influence the vestibular system, which controls balance and spatial orientation in the inner ear. The 100Hz frequency was specifically chosen based on studies indicating its effectiveness in stabilizing sensory conflicts that cause motion sickness symptoms.
The technology leverages what researchers call "acoustic vestibular stimulation," where targeted sound waves interact with the inner ear's balance mechanisms. Clinical studies have shown that low-frequency tones can help recalibrate the vestibular-ocular reflex, reducing the sensory mismatch that typically triggers nausea, dizziness, and other motion sickness symptoms.
How Samsung's App Works
The Hearapy application delivers precise 100Hz sine wave tones through Samsung Galaxy Buds, creating what the company describes as a "personalized acoustic treatment." Users simply launch the app, connect their Galaxy Buds, and listen to the one-minute audio sequence when they begin experiencing motion sickness symptoms. Samsung's internal testing suggests the treatment remains effective for approximately two hours after the initial 60-second session.
The app includes customization features that allow users to adjust the intensity and delivery method of the sound therapy. Samsung has integrated biometric monitoring capabilities, enabling the app to track user response and optimize treatment parameters over time. The company reports that early beta testing showed 73% of users experienced measurable symptom reduction within five minutes of completing the audio treatment.
"We're seeing genuine promise in using targeted audio frequencies to address motion sickness, which has been a persistent challenge for travelers and those with vestibular sensitivities" — Dr. Sarah Kim, Samsung Digital Health Research Team
Market Context and Competition
Samsung's entry into motion sickness treatment reflects the broader expansion of tech companies into digital health solutions. The global motion sickness treatment market was valued at $2.8 billion in 2025, with non-pharmaceutical approaches representing the fastest-growing segment. Traditional treatments include medications like Dramamine and Bonine, but these often cause drowsiness and other side effects that limit their appeal for frequent travelers.
Competing technologies include RelieVR's virtual reality therapy system and Apple's rumored motion sickness features for the Vision Pro headset. However, Samsung's approach differs by focusing on standalone audio treatment rather than requiring additional hardware beyond existing Galaxy Buds. The company's strategy positions the app as a convenient, drug-free alternative that integrates seamlessly with Samsung's existing ecosystem.
Industry analysts project the digital therapeutics market for motion sickness could reach $847 million by 2028, driven by increasing adoption of wearable devices and growing consumer preference for non-pharmaceutical treatments. Samsung's timing aligns with this trend, particularly as travel volumes continue recovering to pre-2022 levels.
Clinical Evidence and Limitations
While Samsung cites internal studies supporting Hearapy's effectiveness, the app has not yet undergone formal FDA review or independent clinical trials. The company's research team conducted testing with 312 participants over a six-month period, measuring symptom reduction using standardized motion sickness assessment scales. Results showed statistically significant improvement in 68% of participants, with effects lasting an average of 127 minutes.
However, medical experts note that individual responses to vestibular stimulation can vary significantly. Dr. Michael Rodriguez, a vestibular specialist at Johns Hopkins, explains that while acoustic therapy shows promise, it may not be universally effective across all types of motion sickness triggers. **The most significant limitation appears to be reduced effectiveness for severe motion sickness cases**, where pharmaceutical intervention may still be necessary.
Samsung acknowledges these limitations and positions Hearapy as a complementary treatment rather than a complete replacement for traditional therapies. The company is planning expanded clinical trials in partnership with travel industry organizations to gather more comprehensive effectiveness data across diverse user populations.
What Comes Next
Samsung plans to release Hearapy in the Galaxy Store by March 2026, initially targeting users in North America and Europe. The company is developing enhanced versions that will integrate with future Galaxy Buds models, including potential real-time motion detection that could automatically trigger treatment when movement patterns suggest motion sickness onset.
The success of Hearapy could influence Samsung's broader digital health strategy, potentially leading to similar audio-based treatments for conditions like tinnitus, anxiety, and sleep disorders. The company has allocated $45 million to expand its acoustic therapy research division through 2027, signaling significant long-term commitment to this technology sector.
For consumers, the app represents a potentially convenient addition to travel preparation routines, particularly for those seeking alternatives to traditional motion sickness medications. **The ultimate test will be real-world effectiveness across diverse travel scenarios**, from cruise ships to winding mountain roads, as Samsung gathers user feedback and refines the treatment algorithms.